| Literature DB >> 24527215 |
Francisco Acín1, César Varela1, Ignacio López de Maturana1, Joaquín de Haro1, Silvia Bleda1, Javier Rodriguez-Padilla1.
Abstract
Our aim was to describe our experience with infrapopliteal endovascular procedures performed in diabetic patients with ischemic ulcers and critical ischemia (CLI). A retrospective study of 101 procedures was performed. Our cohort was divided into groups according to the number of tibial vessels attempted and the number of patent tibial vessels achieved to the foot. An angiosome anatomical classification of ulcers were used to describe the local perfusion obtained after revascularization. Ischemic ulcer healing and limb salvage rates were measured. Ischemic ulcer healing at 12 months and limb salvage at 24 months was similar between a single revascularization and multiple revascularization attempts. The group in whom none patent tibial vessel to the foot was obtained presented lower healing and limb salvage rates. No differences were observed between obtaining a single patent tibial vessel versus more than one tibial vessel. Indirect revascularization of the ulcer through arterial-arterial connections provided similar results than those obtained after direct revascularization via its specific angiosome tibial artery. Our results suggest that, in CLI diabetic patients with ischemic ulcers that undergo infrapopliteal endovascular procedures, better results are expected if at least one patent vessel is obtained and flow is restored to the local ischemic area of the foot.Entities:
Year: 2014 PMID: 24527215 PMCID: PMC3914461 DOI: 10.1155/2014/270539
Source DB: PubMed Journal: Int J Vasc Med ISSN: 2090-2824
Figure 1Angiosomes of the foot. Calcaneal branch (1); medial plantar branch (2); and lateral plantar branch (3) of the posterior tibial artery; dorsalis pedis angiosome (4); anterior branch (5) and calcaneal branch (6) of the peroneal artery.
Basal characteristics of the subjects included.
| Basal characteristics |
|
|---|---|
| Age (years) | 72 (64–77) |
| Males | 62 (61.4%) |
| Smoking history | 75 (74.3%) |
| Dyslipidemia | 33 (32.7%) |
| Hypertension | 73 (72.3%) |
| Ischemic heart disease | 30 (29.7%) |
| Chronic obstructive pulmonary disease | 6 (5.9%) |
| Stroke | 20 (19.8%) |
| Preoperative ABI* | 0.54 (0.40–0.67) |
| Noncompressible ABI* | 54 (53.5%) |
| Infected ulcers | 37 (36.6%) |
| Injured angiosome | |
| Dorsalis pedis angiosome | 79 (78.2%) |
| Medial plantar branch angiosome | 54 (53.5%) |
| Lateral plantar branch angiosome | 26 (25.7%) |
| Posterior tibial a. calcaneal angiosome | 11 (10.9%) |
| Peroneal a. calcaneal angiosome | 9 (8.9%) |
| Peroneal a. anterior angiosome | 2 (2.0%) |
*ABI: ankle-brachial index.
TASC-II classification for the worst lesion treated and perioperative data of the subjects included.
| Perioperative data |
|
|---|---|
| TASC-B | 6 (5.9%) |
| TASC-C | 15 (14.9%) |
| TASC-D | 80 (79.2%) |
| Combined treatment* | 56 (55.4%) |
| Debridement | 11 (10.9%) |
| Minor amputation | 28 (27.7%) |
| Multiple revascularization | 52 (51.5%) |
| Runoff 0 | 16 (15.8%) |
| Runoff 1 | 64 (63.4%) |
| Runoff > 1 | 21 (20.8%) |
| DR# | 46 (54.1%) |
| IR† “through collaterals” | 22 (25.9%) |
| IR† “without collaterals” | 17 (20.0%) |
| Postoperative ABI& | 0.84 (0.69–0.93) |
| MACE+ at 30 days | 3 (3.0%) |
| MALE | 3 (3.0%) |
| Major amputation at 30 days | 2 (2.0%) |
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #DR: direct revascularization; †IR: indirect revascularization; &ABI: ankle-brachial index; +MACE: major adverse cardiovascular event; MALE: major adverse limb event.
Basal characteristics according to the number of tibial vessels attempted for revascularization.
| Basal characteristics | SR# ( | MR† ( |
|
|---|---|---|---|
| Age (years) | 72 (66–80) | 72 (63–76) | 0.39 |
| Males | 24 (48.9%) | 38 (73.0%) |
|
| Smoking history | 30 (61.2%) | 45 (86.5%) |
|
| Dyslipidemia | 18 (36.7%) | 15 (28.8%) | 0.39 |
| Hypertension | 36 (73.5%) | 37 (71.2%) | 0.79 |
| Ischemic heart disease | 15 (30.6%) | 15 (28.8%) | 0.84 |
| Chronic obstructive pulmonary disease | 3 (6.1%) | 3 (5.8%) | 0.94 |
| Stroke | 10 (10.4%) | 10 (19.2%) | 0.88 |
| Preoperative ABI* | 0.54 (0.44–0.68) | 0.54 (0.35–0.67) | 0.55 |
| Noncompressible ABI* | 24 (49.0%) | 30 (57.7%) | 0.38 |
| Infected ulcers | 17 (34.7%) | 20 (38.5%) | 0.69 |
| Injured angiosome | |||
| Dorsalis pedis angiosome | 40 (81.6%) | 39 (75.0%) | 0.42 |
| Medial plantar branch angiosome | 25 (51.0%) | 29 (55.8%) | 0.63 |
| Lateral plantar branch angiosome | 15 (30.6%) | 11 (21.2%) | 0.27 |
| Posterior tibial a. calcaneal angiosome | 6 (12.2%) | 5 (9.6%) | 0.67 |
| Peroneal a. calcaneal angiosome | 4 (8.2%) | 5 (9.6%) | 0.53 |
| Peroneal a. anterior angiosome | 0 (0%) | 2 (2.0%) | 0.49 |
*ABI: ankle-brachial index; #SR: single revascularization; †MR: multiple revascularization.
TASC-II classification for the worst lesion treated and perioperative data according to the number of tibial vessels attempted for revascularization.
| Perioperative data | SR+ ( | MR |
|
|---|---|---|---|
| TASC-B | 4 (8.2%) | 2 (3.8%) | 0.35 |
| TASC-C | 7 (14.3%) | 8 (15.4%) | 0.87 |
| TASC-D | 38 (77.6%) | 42 (80.8%) | 0.69 |
| Combined treatment* | 32 (65.3%) | 24 (46.2%) |
|
| Debridement | 6 (12.2%) | 5 (9.6%) | 0.67 |
| Minor amputation | 14 (28.6%) | 14 (26.9%) | 0.85 |
| Runoff 0 | 10 (20.4%) | 6 (11.5%) | 0.22 |
| Runoff 1 | 36 (73.5%) | 28 (53.8%) |
|
| Runoff > 1 | 3 (6.1%) | 18 (34.6%) |
|
| Postoperative ABI# | 0.90 (0.67–0.94) | 0.83 (0.68–0.92) | 0.86 |
| MACE† at 30 days | 2 (4.1%) | 1 (1.9%) | 0.61 |
| MALE& at 30 days | 1 (2.0%) | 2 (3.8%) | 0.59 |
| Major amputation at 30 days | 0 (0%) | 2 (3.8%) | 0.49 |
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular events; &MALE: major adverse limb events; +SR: single revascularization; MR: multiple revascularization.
Figure 2Ischemic ulcer healing at 12 months (a) and limb salvage at 24 months according to number of tibial vessels attempted for endovascular treatment. SR: single revascularization (Blue line); MR: multiple revascularization (red line). The standard error was <10% for the data shown.
Basal characteristics according to the patent tibial vessels achieved to the foot.
| Basal characteristics |
| |||||
|---|---|---|---|---|---|---|
| Runoff 0 ( | Runoff 1 ( | Runoff > 1 ( | Runoff > 1 versus runoff 1 | Runoff > 1 versus runoff 0 | Runoff 1 versus runoff 0 | |
| Age (years) | 74 (59–79) | 72 (64–77) | 70 (63–75) | 0.46 | 0.57 | 0.87 |
| Males | 12 (75.0%) | 35 (54.7%) | 15 (71.4%) | 0.17 | 0.80 | 0.14 |
| Smoking history | 13 (81.3%) | 43 (67.2%) | 19 (90.5%) |
| 0.41 | 0.36 |
| Dyslipidemia | 7 (43.8%) | 19 (29.7%) | 7 (33.3%) | 0.75 | 0.51 | 0.28 |
| Hypertension | 10 (62.5%) | 48 (75.0%) | 15 (71.4%) | 0.74 | 0.56 | 0.31 |
| Ischemic heart disease | 4 (25.0%) | 16 (25.0%) | 10 (47.6%) |
| 0.16 | 0.19 |
| Chronic obstructive pulmonary disease | 0 (0%) | 6 (9.4%) | 0 (0%) | 0.32 | n.a | 0.34 |
| Stroke | 2 (12.5%) | 10 (15.6%) | 8 (38.1%) |
|
| 0.55 |
| Preoperative ABI* | 0.46 (0.35–0.56) | 0.55 (0.43–0.68) | 0.61 (0.37–0.65) | 0.55 | 0.28 | 0.21 |
| Noncompressible ABI* | 10 (62.5%) | 31 (48.4%) | 13 (61.9%) | 0.28 | 0.97 | 0.31 |
| Infected ulcers | 5 (31.3%) | 24 (37.5%) | 8 (38.1%) | 0.96 | 0.66 | 0.64 |
| Injured angiosome | ||||||
| Dorsalis pedis angiosome | 14 (87.5%) | 51 (79.7%) | 14 (66.7%) | 0.22 | 0.24 | 0.72 |
| Medial plantar branch angiosome | 9 (56.3%) | 32 (50.0%) | 13 (61.9%) | 0.34 | 0.72 | 0.65 |
| Lateral plantar branch angiosome | 4 (25.0%) | 18 (28.1%) | 4 (19.0%) | 0.56 | 0.70 | 0.53 |
| Posterior tibial a. calcaneal angiosome | 1 (6.3%) | 6 (9.4%) | 4 (19.0%) | 0.25 | 0.36 | 0.57 |
| Peroneal a. calcaneal angiosome | 1 (6.3%) | 4 (6.3%) | 4 (19.0%) | 0.09 | 0.36 | 0.68 |
| Peroneal a. anterior angiosome | 0 (0%) | 2 (3.1%) | 0 (0%) | 0.56 | n.a | 0.63 |
*ABI: ankle-brachial index.
TASC-II classification for the worst lesion treated and perioperative data according to the patent tibial vessels achieved to the foot.
| Perioperative data |
| |||||
|---|---|---|---|---|---|---|
| Runoff 0 ( | Runoff 1 ( | Runoff > 1 ( | Runoff > 1 versus runoff 1 | Runoff > 1 versus runoff 0 | Runoff 1 versus runoff 0 | |
| TASC-B | 0 (0%) | 5 (7.8%) | 1 (4.8%) | 0.63 | 0.37 | 0.57 |
| TASC-C | 4 (25.0%) | 9 (14.1%) | 2 (9.5%) | 0.72 | 0.20 | 0.28 |
| TASC-D | 12 (75.0%) | 50 (78.1%) | 18 (85.7%) | 0.54 | 0.43 | 0.74 |
| Combined treatment* | 9 (56.3%) | 25 (39.1%) | 11 (52.4%) | 0.28 | 0.81 | 0.21 |
| Multiple revascularization | 6 (11.5%) | 28 (53.8%) | 18 (34.6%) |
|
| 0.65 |
| Debridement | 3 (18.8%) | 6 (9.4%) | 2 (9.5%) | 0.98 | 0.63 | 0.37 |
| Minor amputation | 6 (37.5%) | 19 (29.7%) | 3 (14.3%) | 0.25 | 0.13 | 0.54 |
| Postoperative ABI# | 0.52 (0.57–0.66) | 0.88 (0.73–0.93) | 0.90 (0.77–0.97) | 0.54 |
|
|
| MACE† at 30 days | 0 (0%) | 3 (4.7%) | 0 (0%) | 0.57 | n.a | 0.50 |
| MALE& at 30 days | 1 (4.8%) | 2 (3.1%) | 0 (0%) | 0.57 | 0.56 | 0.63 |
| Major amputation at 30 days | 1 (4.8%) | 1 (1.6%) | 0 (0%) | 0.43 | 0.56 | 0.80 |
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular event; &MALE: major adverse limb event.
Figure 3Ischemic ulcer healing at 12 months (a) and limb salvage at 24 months according to number of patent tibial vessels achieved to the foot. Runoff 0 = none patent tibial vessel achieved (blue line); Runoff 1 = one patent tibial vessel achieved (red line); Runoff >1 = more than one patent tibial vessel achieved (black line). The standard error was >10% for the data shown in dashed lines.
Basal characteristics according to the local perfusion of the ischemic ulcer.
| Basal characteristics |
| |||||
|---|---|---|---|---|---|---|
| DR# ( | IR† “through collaterals” ( | IR†“without collaterals” ( | DR# versus IR† “through collaterals” | DR# versus IR† “without collaterals” | IR# “through collaterals versus IR† “without collaterals” | |
| Age (years) | 72 (63–78) | 72 (68–75) | 69 (63–77) | 0.94 | 0.99 | 0.60 |
| Males | 30 (65.2%) | 11 (50.0%) | 9 (52.9%) | 0.23 | 0.37 | 0.85 |
| Smoking history | 36 (78.3%) | 15 (68.2%) | 11 (64.7%) | 0.36 | 0.27 | 0.81 |
| Dyslipidemia | 13 (28.3%) | 9 (40.9%) | 4 (23.5%) | 0.29 | 0.70 | 0.25 |
| Hypertension | 31 (67.4%) | 18 (81.8%) | 14 (82.4%) | 0.26 | 0.35 | 0.96 |
| Ischemic heart disease | 17 (36.9%) | 5 (22.7%) | 4 (23.5%) | 0.24 | 0.31 | 0.95 |
| Chronic obstructive pulmonary disease | 3 (6.5%) | 2 (9.1%) | 1 (5.9%) | 0.65 | 0.92 | 0.70 |
| Stroke | 9 (19.6%) | 6 (27.3%) | 3 (17.3%) | 0.47 | 0.86 | 0.70 |
| Preoperative ABI* | 0.50 (0.41–0.68) | 0.60 (0.48–0.74) | 0.64 (0.32–0.67) | 0.30 | 0.79 | 0.48 |
| Noncompressible ABI* | 25 (54.3%) | 9 (40.9%) | 7 (41.2%) | 0.30 | 0.75 | 0.26 |
| Infected ulcers | 6 (35.3%) | 8 (36.4%) | 18 (39.1%) | 0.82 | 0.78 | 0.94 |
| Injured angiosome | ||||||
| Dorsalis pedis angiosome | 37 (80.4%) | 16 (72.7%) | 12 (70.6%) | 0.47 | 0.40 | 0.88 |
| Medial plantar branch angiosome | 24 (52.2%) | 11 (50.0%) | 10 (58.8%) | 0.86 | 0.63 | 0.58 |
| Lateral plantar branch angiosome | 10 (21.7%) | 9 (40.9%) | 3 (17.6%) | 0.09 | 0.51 | 0.16 |
| Posterior tibial a. calcaneal angiosome | 5 (10.9%) | 2 (9.1%) | 3 (17.6%) | 0.59 | 0.67 | 0.63 |
| Peroneal a. calcaneal angiosome | 5 (10.9%) | 1 (4.5%) | 2 (11.8%) | 0.65 | 0.61 | 0.57 |
| Peroneal a. anterior angiosome | 2 (4.3%) | 0 (0%) | 0 (0%) | 0.45 | 0.53 | n.a |
*ABI: ankle-brachial index; #DR: direct revascularization; †IR: indirect revascularization.
TASC-II classification for the worst lesion treated and perioperative data according to the local perfusion of the ischemic ulcer.
| Perioperative data |
| |||||
|---|---|---|---|---|---|---|
| DR+ ( | IR | IR | DR+ versus IR “through collaterals” | DR+ versus IR | IR | |
| TASC-B | 3 (6.5%) | 3 (13.6%) | 0 (0%) | 0.38 | 0.55 | 0.24 |
| TASC-C | 4 (8.7%) | 3 (13.6%) | 4 (23.5%) | 0.67 | 0.19 | 0.67 |
| TASC-D | 39 (84.8%) | 16 (72.7%) | 13 (76.5%) | 0.23 | 0.46 | 0.79 |
| Combined treatment* | 20 (43.5%) | 7 (31.8%) | 3 (17.6%) |
|
| 0.46 |
| Debridement | 4 (8.7%) | 2 (9.1%) | 2 (11.8%) | 0.95 | 0.65 | 0.78 |
| Minor amputation | 12 (26.1%) | 7 (31.8%) | 3 (17.6%) | 0.62 | 0.74 | 0.46 |
| Multiple revascularization | 31 (67.4%) | 8 (36.4%) | 7 (41.2%) |
|
| 0.75 |
| Runoff 1 | 28 (60.9%) | 20 (90.9%) | 16 (94.1%) |
|
| 0.70 |
| Runoff > 1 | 18 (39.1%) | 2 (9.1%) | 1 (5.9%) |
|
| 0.70 |
| Postoperative ABI# | 0.85 (0.70–0.95) | 0.91 (0.82–0.95) | 0.80 (0.65–0.91) | 0.30 | 0.79 | 0.48 |
| MACE† at 30 days | 1 (2.2%) | 2 (9.1%) | 0 (0%) | 0.24 | 0.54 | 0.49 |
| MALE& at 30 days | 1 (2.2%) | 1 (4.5%) | 1 (5.9%) | 0.54 | 0.47 | 0.85 |
| Major amputation at 30 days | 1 (2.2%) | 1 (4.5%) | 0 (0%) | 0.54 | 0.73 | 0.37 |
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular event; &MALE: major adverse limb event; +DR: direct revascularization; IR: indirect revascularization.
Figure 4Ischemic ulcer healing at 12 months (a) and limb salvage at 24 months according to an angiosome classification of the ulcers. IR: indirect revascularization without collaterals (blue line); IRc: indirect revascularization through collateral vessels (black line); DR: direct revascularization (red line). The standard error was >10% for the data shown in dashed lines.